


Figure 3-figure supplement 1


A



B

FcγRIIb genotype	232I	232I	232I	232T
treatment	PBS	anti-CD4	anti-CD20	PBS
FlaB positive	4/13 (31%)	3/10 (30%)	6/10 (60%)	0/7 (0%)

C



D

